SYRE Earnings Spyre Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–19 of 19
| Q2 2026 | 2026-06-30 | -1.09 | 2026-08-04 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.74 | 2026-05-05 | 10-Q |
| Q3 2025 | 2025-09-30 | -1.24 | 2025-11-04 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.09 | 2025-08-05 | 10-Q |
| Q3 2024 | 2024-09-30 | -3.43 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | -2.02 | 2024-08-07 | 10-Q |
| Q1 2024 | 2024-03-31 | -1.20 | 2024-05-09 | 10-Q |
| FY 2023 | 2023-12-31 | -49.12 | 2024-02-29 | 10-K |
| Q3 2024 | 2023-09-30 | -69.57 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -62.03 | 2024-08-07 | 10-Q |
| Q1 2024 | 2023-03-31 | -4.89 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -24.86 | 2024-02-29 | 10-K |
| Q3 2023 | 2022-09-30 | -20.17 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.63 | 2023-08-11 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.37 | 2023-05-11 | 10-Q |
| FY 2023 | 2021-12-31 | -25.02 | 2024-02-29 | 10-K |
| Q3 2022 | 2021-09-30 | -0.69 | 2022-11-03 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.38 | 2022-08-04 | 10-Q |
| FY 2022 | 2020-12-31 | -1.52 | 2023-03-02 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.